Immutrex (Methotrexate)

Methotrexate blocks dihydrofolate reductase, reducing tetrahydrofolate levels needed for DNA synthesis. This limits the proliferation of rapidly dividing cells, including immune cells that drive inflammation and cancer cells. Additionally, methotrexate increases extracellular adenosine, which has anti‑inflammatory properties that help control autoimmune disease activity.

The exact dose of Immutrex is set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosing may be adjusted over time to balance efficacy with safety, and patients should follow the individualized regimen provided by their healthcare professional.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk and may harm the infant. Effective contraception is required for both men and women during treatment and for several months after discontinuation.

To request Immutrex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Immutrex (methotrexate) is a conventional synthetic DMARD that is often used as first‑line therapy because of its broad efficacy, extensive clinical experience, and lower cost compared with biologic agents. Biologics target specific cytokines or cells and may be added when methotrexate alone does not achieve disease control, but they generally require injection or infusion and have distinct safety profiles.

Immutrex should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return the product to refrigeration promptly.

Immutrex is supplied as a sterile injection solution for subcutaneous administration. A healthcare professional injects the prescribed dose into the subcutaneous tissue, typically in the abdomen or thigh, using aseptic technique. Patients may be taught self‑injection after appropriate training, but the initial administration is usually performed by a qualified provider.

The most serious adverse events include bone‑marrow suppression leading to pancytopenia, severe hepatic toxicity such as fibrosis or cirrhosis, and pulmonary toxicity manifesting as interstitial pneumonitis. Early detection through regular blood tests, liver function monitoring, and assessment of respiratory symptoms is essential to mitigate these risks.

Immutrex is contraindicated in individuals who are pregnant, planning pregnancy, or breastfeeding. It should also be avoided in patients with severe renal impairment, active liver disease, uncontrolled infections, or known hypersensitivity to methotrexate or any component of the formulation. Clinicians must evaluate each patient’s medical history before initiating therapy.